Health ❯ Cancer Treatment

Immunotherapy

FDA Regulations CAR-T Therapy Surgery Clinical Trials Immune Checkpoint Inhibitors Immune Checkpoint Blockade Vaccine Design DDR Inhibitors mRNA Technology Cellular Therapy

Dual T‑Cell Engager Combo Shows Deep, Durable PSA Responses at Optimized Dose in mCRPC

The phase 1 RP2R cohort found strong PSA declines with an acceptable safety profile that prompted a phase 3 confirmatory trial.

Stories older than 24h

Personalized mRNA Vaccine Cuts Melanoma Recurrence by 42% in Phase 3 Trial

Imdelltra Plus Imfinzi Cuts Death Risk by 58% in Extensive‑Stage Small Cell Lung Cancer

FDA Expands Anktiva Label to Treat BCG‑Unresponsive High‑Grade Papillary‑Only Bladder Cancer

FDA Approves Tecentriq With Chemotherapy for Stage III dMMR Colon Cancer

AECC Sets 70% Cancer Survival Target and Flags New Trials

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Testosterone Loss Linked to Faster Glioblastoma Growth in Men

ImmunityBio Securities Fight Intensifies After FDA Rebuke Over Anktiva Claims

Investor Lawsuits Build After FDA Rebukes ImmunityBio Over Anktiva Promotion

James Valentine Retires From ABC Radio Sydney After Cancer Recurrence

Zydus Launches Low-Cost Nivolumab Biosimilar Tishtha in India After Court Greenlight

Brain Reward Training Linked to Higher Antibody Response After Hepatitis B Vaccine

Breast Tumors Derail Brain Stress Rhythms as Time-Specific Neural Reset Shrinks Mouse Cancers

OxLDL-Targeted CAR Tregs Cut Mouse Plaque 70% in Penn Study, Prompting Cartio Therapeutics

DeepMind–Yale AI Identifies Drug Candidate That Raises Tumor Antigen Signals by 50% in Lab Tests

UW Engineers Program Proteins to Make Logic‑Gated Decisions for Targeted Drug Delivery

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform

Mouse Studies Link Respiratory Infections to Breast Cancer Reactivation as Human Evidence Faces Scrutiny

Teddi Mellencamp Takes Immunotherapy Break After Scans Show Tumor Shrinkage